Company Focus
Teva Pharmaceutical Industries
Latest Teva Pharmaceutical Industries News
Biotechnology
Teva Pharmaceutical has received a green light from the US regulator for its biologic Ajovy (fremanezumab) to be used for migraine prevention in children, marking a first for pediatric treatment in this area. 6 August 2025
Related News
Insights
Company Spotlight
A biopharmaceutical company focused on developing tumor infiltrating lymphocyte (TIL) therapies for patients with cancer.
Latest News & Features of interest to Teva Pharmaceutical Industries
Biotechnology
US biotech major Biogen reported a 7% rise in its second quarter revenue Friday, with sales of $2.45 billion. 1 August 2025
Generics
Second quarter 2025 revenues at Teva Pharmaceutical Industries came in at $4.18 billion, flat in US dollars, or a decrease of 1% in local currency terms, compared to the same period of 2024. 31 July 2025
Pharmaceutical
Bristol Myers Squibb has posted better-than-expected second-quarter 2025 results, driven by strong sales of its blood thinner Eliquis (apixaban) and cancer treatments Opdivo (nivolumab) and Revlimid (lenalidomide). 31 July 2025
Pharmaceutical
Shares in French pharma major Sanofi were 6% lower late Thursday after the presentation of the company’s second quarter financial results and latest guidance. 31 July 2025
Pharmaceutical
Shares of US pharma major AbbVie were up 6.1% at $200.96 in pre-market activity, as it announced second-quarter 2025 financial results. 31 July 2025
Biotechnology
Japan’s Eisai and US biotech major Biogen have announced that the latest findings demonstrating the benefits of continuous treatment with Leqembi (lecanemab-irmb), an anti-amyloid beta (Aβ) protofibril antibody for the treatment of early Alzheimer's disease (AD) 31 July 2025
Pharmaceutical
Ipsen has reported second-quarter 2025 sales of 901 million euros ($980 million), up 8% from the same period a year ago. Core earnings per share rose 27% to 6.07 euros ($6.60) as strength in rare disease products offset flat performance in oncology. 31 July 2025
Pharmaceutical
Swedish biotech Oncopeptides has entered into a partnership with Spanish pharmaceutical broker SD Pharma to boost the availability of its cancer drug Pepaxti (melphalan flufenamide) in hospitals across Spain. 30 July 2025
Pharmaceutical
GSK posted a 6% rise in second-quarter sales to £8 billion ($10.7 billion), ahead of analyst forecasts. Pre-tax profits climbed 37% to £1.9 billion, while core earnings per share increased 15% to 46.5p, supported by strength in specialty medicines and vaccines. 30 July 2025
Biotechnology
The UK’s National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the use of AstraZeneca’s Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) as a treatment option for adult patients with advanced or unresectable hepatocellular carcinoma (HCC). 30 July 2025
Latest In Brief for Teva Pharmaceutical Industries
Pharmaceutical
US pharma major AbbVie is considering a $1-billion acquisition of Gilgamesh Pharmaceuticals, Bloomberg News reported on Wednesday, citing people familiar with the matter. 31 July 2025
Latest Relevant Ones To Watch News
UK and USA-listed PureTech Health today announced the launch of a new founded entity to be called Celea Therapeutics. 12 August 2025
18 July 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze